Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Sciatica Treatment Market

Sciatica Treatment Market Trends

Report ID: GMI8504
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Sciatica Treatment Market Trends

Advancements in medical imaging and diagnostics have significantly transformed healthcare by enhancing diagnostic accuracy, improving patient outcomes, and enabling more personalized care.

One of the latest technological advancements in advanced diagnostic tools for sciatica is the utilization of magnetic resonance imaging (MRI). MRI is a detailed 3D scan of both the spine and soft tissues that helps identify how the nerve may be pinched, such as with a herniated disc. MRIs can also detect issues like arthritis that may contribute to sciatica pain. This non-invasive imaging approach provides detailed images of musculature, tendons, ligaments, organs, blood flow, and more, without using radiation.
Additionally, VR technologies are being utilized to enhance the visualization of anatomical structures, aiding in surgical planning, and improving patient education. These advancements contribute to more precise diagnostics and treatment planning for conditions like sciatica.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global sciatica treatment industry was valued at around USD 4.8 billion in 2023 and is expected to reach around USD 10 billion by 2032, driven by the increasing prevalence of sciatica, coupled with growing awareness related to available treatments.

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment was valued at USD 2 billion in 2023 and will continue to gain traction through 2032, as they are more cost-effective, and are known for their effectiveness in reducing pain and inflammation.

North America sciatica treatment market accounted for USD 2 billion in 2023, favored by healthcare education initiatives targeting both healthcare professionals and the public.

Abbott Laboratories, Amneal Pharmaceuticals LLC., Bayer AG, Bristol Myers Squibb, Eliem Therapeutics, Novartis AG, Pfizer Inc., Scilex Holding, Sinfonia Biotherapeutics, and Sorrento Therapeutics.